Breaking News

AlphaRose’s RareLabs Launches, Appoints Rob Freishtat CEO

The drug discovery lab says it is a first-of-its-kind AI- and robotics-enabled platform to design and validate genetic medicines.

Author Image

By: Patrick Lavery

Content Marketing Editor

RareLabs, a modality-agnostic precision drug discovery lab, is publicly launching, and naming Rob Freishtat, MD, its Chief Executive Officer (CEO). The lab is a division of AlphaRose Therapeutics, where Freishtat has been and will continue as Chief Medical Officer (CMO). What RareLabs Will Do RareLabs describes itself as a first-of-its-kind AI- and robotics-enabled platform that designs and validates genetic medicines. These include antisense oligonucleotides (ASOs), small interfering RNAs...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters